Alzheimers vax hope
August 3, 2016
RESEARCHERS at Flinders
University in South Australia
working with US scientists have
made a breakthrough discovery,
which could see a vaccine for
Alzheimer’s disease in just years.
Flinders’ School of Medicine
Professor Nikolai Petrovsky said, “If
we are successful in clinical trials,
in three to five years we could be
well on the way to one of the most
important developments in recent
medical history.”
The proposed vaccine targets
abnormal beta-amyloid and
tau proteins known to trigger
Alzheimer’s, potentially preventing
the disease but also limiting its
effects in people already diagnosed.
Petrovsky is also a director of
SA vaccine research firm Vaxine
Pty Ltd, which has developed a
technology called Advax.
Vaxine has been funded by the
US National Institutes of Health
to develop adjuvants that play a
critical role in maximising vaccine
effectiveness, with Advax a key
component in the development of
the potential Alzheimer’s vaccine.
The proteins are targeted using
an “exceptional” universal vaccine
platform called MultiTEP.
Extensive clinical trials will be
required to ensure the vaccine
is suitable for public use under
globally recognised standards.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 16
